March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Registrational Trial of AFM13 Will Continue Following Success of Preplanned Interim AnalysisMarch 11th 2021
A phase 2 trial of single-agent AFM13, a bispecific tetravalent innate cell engager that binds to CD30, will continue following positive results of a preplanned interim futility analysis.
Frederick Locke, MD, and Michael Jain, MD, PhD, on Why Some Patients With Lymphoma Do Not Respond to Cellular ImmunotherapyMarch 2nd 2021
CancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.
In B-Cell NHL, Off-the-Shelf NK Immunotherapy Shows Promise When Used With Chemotherapy and ASCTFebruary 19th 2021
Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.
Clinical Practice Guidelines Update: SITC Provides Clinicians With Up-to-Date Immunotherapy Recommendations for LymphomaFebruary 16th 2021
Guidelines released by the Society for Immunotherapy of Cancer are intended to provide clinicians with the most current thinking on how experts can integrate immunotherapy into the treatment of patients with lymphoma.
MRD Positivity Associated With Worse PFS, OS Post-Induction, Consolidation in Patients With MCLFebruary 4th 2021
“MRD status after both induction therapy and consolidation therapy showed prognostic value. This may provide information for deciding timing of MRD assessment,” wrote the study investigators.
Results Show Promising Efficacy in MCL With Next-Generation BTK Inhibitor LOXO-305January 7th 2021
Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the Bruton tyrosine kinase inhibitor LOXO-305, especially in those with heavily pretreated mantle cell lymphoma.
Laurie H. Sehn, MD, on the Impact of Additional Findings From the GO29365 Study in DLBCLDecember 24th 2020
Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.
MEDI-570 Evokes Durable Reponses in Patients with R/R T-Cell LymphomasDecember 8th 2020
A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.
Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASHDecember 7th 2020
The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.
IFRT Appears Safe, Effective Standard of Care for Some Pediatric Patients with High-Risk cHLNovember 25th 2020
A study presented at ASTRO suggested that response-based consolidation involved-field radiation therapy appears to be a safe and effective standard of care for a cohort of pediatric patients with high-risk classical Hodgkin lymphoma.
FDA Will Not Complete Review of BLA for Lisocabtagene Maraleucel By PDUFA DateNovember 17th 2020
The priority review of the biologics license application for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies will not be completed by the prescription drug user fee act date.
Phase 3 CHRONOS-3 Study Meets Primary End Point for Indolent Non-Hodgkin’s LymphomaOctober 14th 2020
The study is evaluating copanlisib (Aliqopa) in combination with rituximab (Rituxan) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after 1 or more prior lines of rituximab-containing therapy.
AUTO3, Pembrolizumab Combo Appears Safe, Elicits Durable Responses in Relapsed/Refractory DLBCLSeptember 27th 2020
Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
FDA Grants Priority Review to sNDA for Crizotinib to Treat Pediatric ALK+ ALCLSeptember 23rd 2020
The supplemental new drug application seeks approval for crizotinib (Xalkori) to treat pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is ALK positive.
Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 StudyJuly 14th 2020
The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.